| $385M | ||
| $350M | ||
| $215M | ||
| $88M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $102,411,160 | 71 | 100 |
| Turner Christopher Durant | Chief Medical Officer | 0 | $0 | 2 | $721,320 | $-721,320 |
| Pelish Henry E. | Chief Scientific Officer | 0 | $0 | 13 | $4.92M | $-4.92M |
| Shair Matthew | director | 0 | $0 | 4 | $6.99M | $-6.99M |
| Noci Darlene | Chief Development Officer | 0 | $0 | 15 | $7.12M | $-7.12M |
| Miller Deborah Ann | Chief Legal Officer | 0 | $0 | 10 | $11.15M | $-11.15M |
| Balcom Alexandra | Chief Financial Officer | 0 | $0 | 15 | $14.58M | $-14.58M |
| Porter James Richard | President and CEO | 0 | $0 | 11 | $21.49M | $-21.49M |
| Flynn James E | Director by Deputization | 0 | $0 | 1 | $35.44M | $-35.44M |
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Over the last 12 months, insiders at Nuvalent, Inc. have bought $0 and sold $102.41M worth of Nuvalent, Inc. stock.
On average, over the past 5 years, insiders at Nuvalent, Inc. have bought $52.71M and sold $96.56M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 650,000 shares for transaction amount of $21.77M was made by Flynn James E (director) on 2022‑11‑03.
| 2026-01-29 | Sale | Noci Darlene | Chief Development Officer | 5,500 0.0075% | $102.08 | $561,422 | +0.76% | |
| 2026-01-22 | Sale | Miller Deborah Ann | Chief Legal Officer | 14,300 0.0193% | $110.16 | $1.58M | -6.07% | |
| 2026-01-21 | Sale | Miller Deborah Ann | Chief Legal Officer | 700 0.001% | $109.84 | $76,888 | -4.84% | |
| 2026-01-06 | Sale | Porter James Richard | President and CEO | 9,543 0.013% | $97.16 | $927,244 | +7.29% | |
| 2026-01-06 | Sale | Balcom Alexandra | Chief Financial Officer | 3,181 0.0043% | $97.16 | $309,081 | +7.29% | |
| 2026-01-06 | Sale | Pelish Henry E. | Chief Scientific Officer | 2,664 0.0036% | $97.17 | $258,848 | +7.29% | |
| 2026-01-06 | Sale | Turner Christopher Durant | Chief Medical Officer | 3,181 0.0043% | $97.16 | $309,081 | +7.29% | |
| 2026-01-06 | Sale | Miller Deborah Ann | Chief Legal Officer | 2,589 0.0035% | $97.16 | $251,560 | +7.29% | |
| 2026-01-06 | Sale | Noci Darlene | Chief Development Officer | 3,181 0.0043% | $97.16 | $309,081 | +7.29% | |
| 2026-01-05 | Sale | Porter James Richard | President and CEO | 17,890 0.0244% | $97.32 | $1.74M | +6.45% | |
| 2026-01-05 | Sale | Balcom Alexandra | Chief Financial Officer | 4,236 0.0058% | $97.32 | $412,239 | +6.45% | |
| 2026-01-05 | Sale | Pelish Henry E. | Chief Scientific Officer | 513 0.0007% | $96.06 | $49,279 | +6.45% | |
| 2026-01-05 | Sale | Pelish Henry E. | Chief Scientific Officer | 2,496 0.0034% | $97.32 | $242,905 | +6.45% | |
| 2026-01-05 | Sale | Turner Christopher Durant | Chief Medical Officer | 4,236 0.0058% | $97.32 | $412,239 | +6.45% | |
| 2026-01-05 | Sale | Miller Deborah Ann | Chief Legal Officer | 4,363 0.006% | $97.32 | $424,598 | +6.45% | |
| 2026-01-05 | Sale | Noci Darlene | Chief Development Officer | 4,236 0.0058% | $97.32 | $412,239 | +6.45% | |
| 2026-01-02 | Sale | Miller Deborah Ann | Chief Legal Officer | 10,000 0.0137% | $100.51 | $1.01M | +3.27% | |
| 2025-12-30 | Sale | Noci Darlene | Chief Development Officer | 4,000 0.0055% | $100.04 | $400,179 | +3.37% | |
| 2025-12-08 | Sale | Balcom Alexandra | Chief Financial Officer | 7,084 0.01% | $110.32 | $781,537 | -3.49% | |
| 2025-11-28 | Sale | Noci Darlene | Chief Development Officer | 4,000 0.0055% | $108.58 | $434,319 | -4.16% |
| Flynn James E | Director by Deputization | 8299225 11.4147% | $848.51M | 3 | 2 | +13.77% |
| Porter James Richard | President and CEO | 278629 0.3832% | $28.49M | 0 | 16 | |
| Shair Matthew | director | 201672 0.2774% | $20.62M | 0 | 43 | |
| Balcom Alexandra | Chief Financial Officer | 81733 0.1124% | $8.36M | 0 | 24 | |
| Pelish Henry E. | Chief Scientific Officer | 65888 0.0906% | $6.74M | 0 | 16 | |
| Miller Deborah Ann | Chief Legal Officer | 59634 0.082% | $6.1M | 0 | 41 | |
| Noci Darlene | Chief Development Officer | 58117 0.0799% | $5.94M | 0 | 52 | |
| Turner Christopher Durant | Chief Medical Officer | 55130 0.0758% | $5.64M | 0 | 9 | |
| Hack Andrew A. F. | director | 1447267 1.9906% | $147.97M | 2 | 2 | +4.53% |
| Conley Emily | director | 2507 0.0034% | $256,315.68 | 0 | 6 | |
| Protopapas Anna | director | 0 0% | $0 | 0 | 1 |
$211,610,344 | 91 | 38.45% | $11.07B | |
$108,876,545 | 67 | 72.81% | $9.46B | |
$224,382,625 | 44 | 27.62% | $5.31B | |
$88,307,390 | 38 | -1.70% | $10.21B | |
$477,065,869 | 34 | 82.05% | $5.35B | |
$1,801,511 | 23 | 18.58% | $8.92B | |
$11,859,102 | 17 | 18.62% | $8.15B | |
$103,944,213 | 17 | 5.95% | $6.84B | |
$1,279,017 | 16 | 51.12% | $9.24B | |
$75,296,863 | 13 | 33.79% | $6.7B | |
$57,686,748 | 13 | 21.11% | $5.55B | |
$9,976,473 | 12 | 29.52% | $6.94B | |
$2,477,801 | 11 | 4.98% | $5.43B | |
$11,898,979 | 10 | 54.58% | $8.35B | |
$20,499,451 | 9 | 71.54% | $5.72B | |
$55,713,031 | 8 | -0.36% | $5.93B | |
$948,235 | 8 | 15.56% | $9.15B | |
Nuvalent, Inc. (NUVL) | $105,414,951 | 5 | 10.07% | $7.43B |
$41,376,000 | 4 | -12.07% | $7.57B |
| Increased Positions | 150 | +82.87% | 8M | +10.99% |
| Decreased Positions | 75 | -41.44% | 3M | -4.51% |
| New Positions | 46 | New | 2M | New |
| Sold Out Positions | 29 | Sold Out | 2M | Sold Out |
| Total Postitions | 256 | +41.44% | 77M | +6.48% |
| Deerfield Management Company, L.P. | $1.81M | 26.85% | 17.99M | 0 | 0% | 2025-09-30 |
| Fmr Llc | $1.01M | 14.95% | 10.01M | +44,391 | +0.45% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $531,370.00 | 7.87% | 5.27M | 0 | 0% | 2025-09-30 |
| Vanguard Group Inc | $464,369.00 | 6.87% | 4.61M | +80,883 | +1.79% | 2025-09-30 |
| Blackrock, Inc. | $412,012.00 | 6.1% | 4.09M | +39,539 | +0.98% | 2025-09-30 |
| Wellington Management Group Llp | $232,019.00 | 3.43% | 2.3M | +724,491 | +45.96% | 2025-09-30 |
| Janus Henderson Group Plc | $220,706.00 | 3.27% | 2.19M | +406,093 | +22.78% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $182,563.00 | 2.7% | 1.81M | +15,047 | +0.84% | 2025-09-30 |
| Jpmorgan Chase & Co | $168,807.00 | 2.5% | 1.67M | +476,822 | +39.83% | 2025-09-30 |
| State Street Corp | $158,797.00 | 2.35% | 1.57M | +84,468 | +5.67% | 2025-09-30 |